Abstract The clinical and epidemiological characteristics of 111 consecutive cases of visceral leishmaniasis identified from 1980 to 2000 in a Sicilian pediatric hospital were analyzed retrospectively. The mean age of the patients was 1.7 years. All children were HIV negative, but 15% were severely malnourished. Fever and splenomegaly were present in all cases and hepatomegaly in 101 (90.1%) cases. Thrombocytopenia and anemia were both observed in 78 (70.2%) cases and leukopenia in 47 (42.3%) cases. A bone marrow aspirate was obtained in all cases; Leishmania amastigotes were detected in 89 (80.2%) cases. Initial treatment consisted of meglumine antimoniate in 99 (89.2%) patients and amphotericin B in 12 (10.8%) patients. Only two children treated with meglumine antimoniate relapsed. The findings highlight the differences between the cases of visceral leishmaniasis observed in the Mediterranean basin and those observed in other regions. The use of the term “Mediterranean visceral leishmaniasis”, rather than the term “kala-azar”, is proposed for cases observed in the Mediterranean area.

Introduction

Visceral leishmaniasis (VL) is endemic in areas bordering the Mediterranean Sea (Spain, Italy, France, Greece, Morocco, Tunisia), where it is caused by the protozoan Leishmania infantum and is transmitted by the bite of hematophagous sandflies belonging to Phlebotomus spp. The dog constitutes the proven reservoir of the infection.

Sicily is the largest island in the Mediterranean Sea. It was recently estimated that approximately 47% of the Sicilian population live in areas at risk for Leishmania infection, these areas consisting mainly of rural areas, small villages, or peripheral districts of towns where the vector sandfly species are more abundant. During the 1987–1995 period, the annual incidence of VL in the general population was 6 cases per 1,000,000 residents [1].

In comparison with the past, when VL was typically observed more frequently in children, the current age-related epidemiologic features observed in Sicily reflect those reported for other Mediterranean regions of Europe, such as France, Spain, and Greece, where the ratio of childhood to adult cases is approximately 1:1 [1, 2, 3].

Pentavalent antimonial drugs have been used for many decades as standard treatment for VL [4]. They have been used extensively in children and have been demonstrated to be safe and effective. During the last decade, the emergence of Leishmania strains resistant to pentavalent antimonials and the occurrence of side effects have prompted the evaluation of other drugs, including pentamidine and lipid formulations of amphotericin B [4].

We analyzed retrospectively the epidemiologic, clinical, and therapeutic features of 111 children affected by VL and admitted consecutively to our hospital over a 21-year period (1980–2000). This is the hospital where antimonial drugs were employed for the first time in the therapy of VL, in the early part of the 20th century [5].
were performed by seeding bone marrow aspirates into a semisolid blood-agar-based medium (Sloppy Evans medium) generously supplied by Istituto Superiore di Sanità in Rome. Positive cultures were sent to the Istituto Superiore di Sanità, where *Leishmania* strains were characterized by Dr. M. Gramiccia by means of starch electrophoretic analysis of 15 isoenzymes, using the techniques and zymodeme nomenclature of the World Health Organization Collaborating Center (Montpellier, France).

### Results

From January 1980 to December 2000, 111 children were diagnosed with VL. Admissions averaged five per year, without any seasonal variation. The patients’ median age was 1.7 years (range, 4.5 months–11.7 years); 19 (17.1%) patients were aged <12 months. Fifty-six (50.4%) were males. No child was HIV positive. Analysis of the nutritional status of the patients showed that 17 (15.3%) were below the tenth percentile on the weight-for-age growth chart. Two (1.8%) patients had an underlying disease at hospital admission: one was affected by Wilson’s disease, the other one by pseudomembranous conjunctivitis. Twenty-five (22.5%) patients had a concurrent bacterial or viral infection, including acute otitis media (7 patients), respiratory infections (8 patients, upper respiratory infection; 5 patients, bronchitis; and 3 patients, pneumonia), and tonsillitis (2 patients). One girl was an immigrant from Ghana. In all but one case, the disease was contracted in western Sicily. Eighty-nine (80%) patients lived in districts that were located near the foothills of mountains bordering the city or within the city itself. The median time from the onset of symptoms to hospital admission was 15 days (range, 2 days–7 months). Fever and splenomegaly were present at admission in all patients (Table 1).

Interestingly, in two cases a small skin lesion on the face was associated with VL and preceded the onset of full-blown disease. In both cases numerous intracellular and extracellular *Leishmania* amastigotes were present on the smears obtained from the lesions (Fig. 1a).

The most frequently encountered hematological findings were thrombocytopenia and anemia, both of which were observed in 80.4% of the patients. Leukopenia was found in 43.1% of the patients, and <500 neutrophils were present in 9.1% of the patients. Pancytopenia was present in six (5.7%) patients, and both leukopenia and thrombocytopenia without anemia in 28 (26.9%) pa-
Patients. Fifteen (13.5%) patients required blood transfusion due to anemia. The albumin value was <3 g/dl in 31.1% of the patients. In 22.4% of the patients, the albumin value was higher than the globulin value (albumin/globulin inversion). A value of aspartate aminotransferase and of alanine aminotransferase >80 IU/l was reported in 33.3% and 23.6%, respectively (Table 2).

A bone marrow aspirate was obtained from all patients, and *Leishmania* amastigotes were detected in 89 (80.2%) cases. In one case, after two negative examinations of bone marrow, a splenic aspirate was obtained; examination revealed *Leishmania* parasites. Culture from bone marrow aspirate was performed in 41 cases and was positive in 31 (75.6%). *Leishmania infantum* isolates were isoenzymatically characterized: the zymodemes identified were MON 1 in 24 cases and MON 27 and MON 80 in 1 case each. The remaining five strains could not be characterized due to bacterial contamination.

IFAT was performed in 84 (75.7%) cases; it gave a false-negative result in only 2 cases (in these cases, the diagnosis was made by microscopy). The geometric mean titer of anti-*Leishmania* antibody was 227 (range, 0–5,120).

Diagnosis of visceral leishmaniasis was established by direct microscopy of bone marrow together with positive IFAT in 60 patients; by means of IFAT alone in 22 (in 1 of these, diagnosis was confirmed by a positive culture), and by microscopy alone in 29. Diagnosis was made a median of 2 days (range, 0–23 days) after admission.

Ninety-nine (89.2%) patients were treated initially with meglumine antimoniate and 12 (10.8%) patients with L-AmB. Patients were followed-up at the outpatient clinic for a median of 1 year (range, 6 months–3 years) after treatment was completed. Of the 99 patients treated with meglumine antimoniate, 1 was still febrile after 6 days, so treatment was switched to L-AmB. Two patients relapsed within the next 100 days and then were treated with L-AmB; one had been treated with 20 mg/kg for 28 days, the other one with 25 mg/kg per 30 days in two 15-day courses. Of the patients treated with L-AmB, one had been treated for VL with meglumine antimoniate 1 year previously in another part of Italy (Ancona). This case should be considered a relapse. All patients treated with L-AmB recovered, and none relapsed (Table 3). The cutaneous lesion (Fig. 1a) associated with a case of VL persisted after six doses (on day 10) of L-AmB, even though it became slightly less reddish than observed initially. Scarce amastigotes were still present on the smear, so a 10-day course of intralesional meglumine antimoniate (about 20 mg of SbV, given on alternate days) was administered, which resulted in complete resolution of the skin lesion.

Adverse effects while receiving meglumine antimoniate were observed in 16 patients, including rash (3 patients) and dry cough (13 patients). All adverse effects but one (the severe urticarial rash) were transient and self-limited and did not require interruption of treatment. No adverse effects were detected in the 16 patients treated with L-AmB (only a transient rash on day 9 of therapy, possibly not related to therapy).

**Table 2** Hematological and biochemical features of 111 children with visceral leishmaniasis

<table>
<thead>
<tr>
<th>Variable</th>
<th>Median value (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythrocyte count (×10⁶ cells/µl)</td>
<td>3.7 (1.9–5)</td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>7.8 (3.8–12.7)</td>
</tr>
<tr>
<td>Leukocyte count (×10³ cells/µl)</td>
<td>4.3 (1.6–10.9)</td>
</tr>
<tr>
<td>Neutrophil count (×10³ cells/µl)</td>
<td>1 (0.2–3.7)</td>
</tr>
<tr>
<td>Platelets (×10³ cells/µl)</td>
<td>110 (12–362)</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate (mm/h)</td>
<td>73 (9–138)</td>
</tr>
<tr>
<td>C-reactive protein (mg/100 ml)</td>
<td>2.3 (0.3–18.2)</td>
</tr>
<tr>
<td>Total protein (g/dl)</td>
<td>7.3 (4.5–10.4)</td>
</tr>
<tr>
<td>Albumin (g/dl)</td>
<td>3.3 (1.4–5.3)</td>
</tr>
<tr>
<td>Gammaglobulin (g/dl)</td>
<td>2.3 (0.6–6.6)</td>
</tr>
<tr>
<td>Aspartate aminotransferase (IU/l)</td>
<td>53 (19–847)</td>
</tr>
<tr>
<td>Alanine aminotransferase (IU/l)</td>
<td>33 (8–497)</td>
</tr>
</tbody>
</table>

**Fig. 1** a Small, reddish macula observed on the face of a child with visceral leishmaniasis caused by a viscerotropic strain (MON1) of *Leishmania infantum*. Inset: Giemsa-stained smear showing intracellular and extracellular *Leishmania* amastigotes (original magnification, ×1000) b Typical presentation of Old World cutaneous leishmaniasis (oriental sore, caused by a dermotropic strain of *Leishmania infantum*) in the Sicilian region.
A reduction of spleen size up to half of the size initially palpated was observed a median of 10 days (range, 4–28 days) after treatment was begun. Overall, patients became afebrile a median of 4 days (range, 1–9 days) after treatment was initiated, whereas hematological restoration occurred a median of 12 days later (range, 9–30 days).

Twelve patients developed nosocomial infections: gastroenteritis (5 patients, caused by rotavirus in 3), chickenpox (1 patient), measles (1 patient), urinary tract infection (1 patient), and maculopapular exanthema caused by infection with human herpesvirus 6 (4 patients).

**Discussion**

The different forms of cutaneous leishmaniasis (i.e., cutaneous leishmaniasis, diffuse cutaneous leishmaniasis, and mucocutaneous leishmaniasis) are classified according to their epidemiology and clinical presentation [9]. Although VL acquired in the Mediterranean area has a different epidemiology and clinical presentation than that acquired in India or in other regions, all forms of VL are generally still referred to using the Hindi term “kala-azar”, even in the latest edition of the two major textbooks of infectious and tropical diseases [9, 10]. Nevertheless, there are many differences between the disease acquired in the Mediterranean basin and other forms contracted elsewhere. These include the *Leishmania* species involved, the lack of post kala-azar dermal leishmaniasis, and the absence of skin hyperpigmentation (Table 4). Therefore, we believe that the term “kala-azar” and VL should not be used interchangeably for cases observed in the Mediterranean basin.

As in other case series describing VL acquired in the Mediterranean area [13, 14, 15], VL in Sicily involved mainly young children; the median age of our patients was 1.7 years, and 26.1% of the children were younger than 12 months. The main clinical and laboratory findings were also similar to those reported in the other Mediterranean countries [13, 14, 15].

A critical issue we would like to highlight is the appearance of lymphadenopathy during the course of VL: this is probably a quite common feature in Sudan (84%) [16, 17], but it is rarer in the Mediterranean basin (36–39%) [13, 14]. Furthermore, in our experience, except for lymphadenopathy of the small posterior cervical lymph nodes, which is a very common but nonspecific finding among children 2–14 years of age, lymphadenopathy was not found in any case. It would be very useful to know if, in the more recently reported pediatric series from the Mediterranean basin [13, 14], the finding of lymphadenopathy was definitely correlated to VL or, as we suppose, it was an occasional finding unrelated to the disease. In the future, we suggest that authors describing VL report the entity and the sites involved in the case of lymphadenopathy.

In contrast to what was reported in the last edition of the Mandell textbook [9], i.e., that “the presence of a hard spleen suggests a hematologic disorder or other diagnosis such as schistosomiasis”, the spleen was hard in almost all of our patients. In fact, on the basis of the above misleading information, several of our patients were initially admitted to the hematologic department.

In two cases we observed a small, noninfiltrated lesion on the skin in which many *Leishmania* amastigotes were seen by microscopy. This kind of lesion preceding VL must be differentiated from the lesions of the typical cutaneous leishmaniasis that occurs in our region (known as “oriental sore” or dry form), which is caused by dermatropic strains of *Leishmania infantum*. It presents as a firm, painless, slow-growing, infiltrated papule and forms a well-circumscribed central ulceration with very few amastigotes (Fig. 1b) [18]. To the best of our knowledge, there are only two previous reports of skin involvement preceding overt VL in the Mediterranean area [19, 20].
Table 4  Characteristic of the four forms of visceral leishmaniasis observed worldwide in otherwise immunocompetent patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mediterranean visceral leishmaniasis</th>
<th>American visceral leishmaniasis</th>
<th>Kala-azar</th>
<th>African kala-azar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main geographical area</td>
<td>Mediterranean basin</td>
<td>northeast Brazil, Central America</td>
<td>India, Pakistan, Nepal, northern and southern China</td>
<td>Sudan, Kenya, Horn of Africa</td>
</tr>
<tr>
<td>Epidemiology Cycle</td>
<td>endemic</td>
<td>endemic</td>
<td>endemic/epidemic</td>
<td>endemic/epidemic</td>
</tr>
<tr>
<td>Reservoir Causative Leishmania species</td>
<td>dogs, foxes, jackals</td>
<td>dogs, foxes, opossums</td>
<td>humans</td>
<td>dogs? humans?</td>
</tr>
<tr>
<td>Vector species and natural habitat</td>
<td>Phlebotomus perniciosus</td>
<td>Phlebotomus argentipes; Lutzomyia longipalpis</td>
<td>Phlebotomus orientalis, Phlebotomus martini</td>
<td></td>
</tr>
<tr>
<td>Male/female ratio</td>
<td>1:1</td>
<td>male&gt;female</td>
<td>6:1</td>
<td>young adults</td>
</tr>
<tr>
<td>Age of patients usually affected</td>
<td>&lt;5 years</td>
<td>young children</td>
<td>young adults</td>
<td>young adults</td>
</tr>
</tbody>
</table>

Clinical manifestations

- Fever: 95–100%
- Splenomegaly: 95–100%
- Hepatomegaly: ~70%
- Skin hyperpigmentation: no
- Lymphadenopathy: 0–39%
- Occurrence of post-kala-azar dermal leishmaniasis: no
- Resistance to antimonial agents: rare

We believe that the differences between American and Mediterranean visceral leishmaniasis are due only to the habits and characteristics of their vectors.

As far as therapy of VL is concerned, pentavalent antimonials are still indicated as the drug of choice due to their availability, low cost, and efficacy. Although it is not feasible to make direct comparisons between the treatment regimens due to several possible selection biases, we found that a 21-day course of meglumine antimoniate 560 mg/m²/day (of SbV) (22.4–26.6 mg/kg/day), gradually increasing the daily dose during the first 3–4 days of therapy, is at least as effective as two 15-day courses or a 28-day course with 20 mg of SbV (the WHO recommended treatment) [2]. Resistance to pentavalent antimonials has been documented in India and Sudan [4], although it does not seem to be a problem in our region; we did, however, observe two relapses.

A 6-day course (on days 1–5 and 10) of therapy with L-AmB was shown to be effective and safe in children with VL. The cost of this regimen for a 15 kg child in our hospital is about $900, while the cost of a 21-day course of meglumine antimoniate (25 mg/kg/day of SbV) for the same child is $10; however, taking into account the length of hospitalization (with a cost of $150 per day) and the risk of acquiring nosocomial infections, in our opinion the balance seems to favor the use of L-AmB as a first choice for the treatment of children with VL in industrialized Mediterranean countries. In this regard, we disagree with the recent Greek recommendation [14], since we do not believe that the outpatient administration of antimonials is feasible due to the potential fatal toxicities of these drugs.

Unfortunately, meglumine antimoniate is currently the only drug approved in Italy for the treatment of VL. However, a multicenter randomized controlled trial (meglumine antimoniate vs. L-AmB) is now under way in Italy in which a pharmaco-economic evaluation also will be performed.

Acknowledgments  This study was supported by AILMI (Associazione Italiana per la Lotta contro le Malattie Infettive. We are very grateful to Prof. A.D.M. Bryceson for his helpful discussion on the manuscript.
References